On Demand | Online
Genome sequencing plays a pivotal role in the COVID-19 pandemic and Illumina NGS has been there from the start. The full sequence of SARS-CoV-2 which was made public back in January 2020 has been crucial for the development of diagnostic and surveillance tools, and is used globally for the development of potential treatments and vaccines. The power of NGS continues to prove essential in our understanding and response to COVID-19.
To support the important COVID-19 work, Illumina has delivered several technological innovations that are powering our comprehensive portfolio of workflow and software solutions to support researchers, epidemiologists and clinicians on the front line in the fight against COVID-19.
Speaker:
Michael Oberholzer
Ph.D. Senior Staff Product Manager, Infectious Disease
Gary Schroth
Ph.D. Vice President & Distinguished Scientist, Emerging Applications
Jonathan Hetzel
Ph.D. Senior Scientist, Emerging Applications
